Enseñanza de la geometría analítica 3D mediada con recursos digitales

Esta experiencia de aula esta apoyada en el uso de ambientes educativos computarizados, cuyo propósito es mejorar habilidades de visualización en el tema de geometría analítica 3D. Es preferible que los estudiantes participantes hayan cursado el espacio de geometría analítica en R2 para que mediante la utilización de un software 3D, puedan responder una serie de preguntas, sobre los conceptos básicos de superficies cuádricas las cuales son presentadas y evaluadas por el mismo software educativo. Las preguntas abordan temas tales como: punto, distancia entre dos puntos, planos, elipsoides, paraboloides, hiperboloides y conos

Incorporación de vídeos como material de apoyo para el desarrollo de habilidades de visualización espacial 3D en los estudiantes de cálculo vectorial de la Universidad del Quindío.

El objetivo de este estudio es evaluar el impacto que tiene la incorporación de videos como material de apoyo para el desarrollo de habilidades de visualización espacial 3D, con la utilización de un software educativo, en estudiantes que cursan la asignatura de cálculo vectorial en la Universidad del Quindío. Cabe resaltar que los estudiantes se están acoplando a la información transmitida en medios digitales. Para cumplir este propósito se pretende explorar las experiencias de los estudiantes frente a este tipo de recursos y describir las diferentes estrategias que los mismos utilizan para resolver los problemas de visualización tanto cuantitativa como cualitativamente, así se analizará la asimilación de contenidos por parte de los estudiantes. Como resultado se espera que los estudiantes tengan una mejora en sus habilidades de visualización espacial, lo que permitirá mejorar el aprendizaje en las prácticas de aula de la Universidad del Quindí

Cancer therapy shapes the fitness landscape of clonal hematopoiesis.

Acquired mutations are pervasive across normal tissues. However, understanding of the processes that drive transformation of certain clones to cancer is limited. Here we study this phenomenon in the context of clonal hematopoiesis (CH) and the development of therapy-related myeloid neoplasms (tMNs). We find that mutations are selected differentially based on exposures. Mutations in ASXL1 are enriched in current or former smokers, whereas cancer therapy with radiation, platinum and topoisomerase II inhibitors preferentially selects for mutations in DNA damage response genes (TP53, PPM1D, CHEK2). Sequential sampling provides definitive evidence that DNA damage response clones outcompete other clones when exposed to certain therapies. Among cases in which CH was previously detected, the CH mutation was present at tMN diagnosis. We identify the molecular characteristics of CH that increase risk of tMN. The increasing implementation of clinical sequencing at diagnosis provides an opportunity to identify patients at risk of tMN for prevention strategies

Cancer therapy shapes the fitness landscape of clonal hematopoiesis.

Acquired mutations are pervasive across normal tissues. However, understanding of the processes that drive transformation of certain clones to cancer is limited. Here we study this phenomenon in the context of clonal hematopoiesis (CH) and the development of therapy-related myeloid neoplasms (tMNs). We find that mutations are selected differentially based on exposures. Mutations in ASXL1 are enriched in current or former smokers, whereas cancer therapy with radiation, platinum and topoisomerase II inhibitors preferentially selects for mutations in DNA damage response genes (TP53, PPM1D, CHEK2). Sequential sampling provides definitive evidence that DNA damage response clones outcompete other clones when exposed to certain therapies. Among cases in which CH was previously detected, the CH mutation was present at tMN diagnosis. We identify the molecular characteristics of CH that increase risk of tMN. The increasing implementation of clinical sequencing at diagnosis provides an opportunity to identify patients at risk of tMN for prevention strategies

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene

To identify novel genes associated with ALS, we undertook two lines of investigation. We carried out a genome-wide association study comparing 20,806 ALS cases and 59,804 controls. Independently, we performed a rare variant burden analysis comparing 1,138 index familial ALS cases and 19,494 controls. Through both approaches, we identified kinesin family member 5A (KIF5A) as a novel gene associated with ALS. Interestingly, mutations predominantly in the N-terminal motor domain of KIF5A are causative for two neurodegenerative diseases: hereditary spastic paraplegia (SPG10) and Charcot-Marie-Tooth type 2 (CMT2). In contrast, ALS-associated mutations are primarily located at the C-terminal cargo-binding tail domain and patients harboring loss-of-function mutations displayed an extended survival relative to typical ALS cases. Taken together, these results broaden the phenotype spectrum resulting from mutations in KIF5A and strengthen the role of cytoskeletal defects in the pathogenesis of ALS.Peer reviewe

General Characteristics of Edaravone Use in the Natural History of ALS and Other Motor Neuron Disorders Consortium Dataset (NeuroBANK™)

Objective: To report percentage and general information on patients receiving edaravone in the clinics members of ALS Natural History Study Consortium. Background: The ALS Natural History Study protocol was developed with the goal of sharing longitudinal natural history data from several ALS multidisciplinary clinics participating in the ALS Natural History Consortium. Edaravone was approved by the FDA in May 2018 as a new treatment for ALS. There is not yet much data available regarding edaravone use in the United States. We report on edaravone use in our clinics since its approval. Design/Methods: All patients followed regularly in seven multidisciplinary ALS clinics are being offered participation in the study. Consenting participants are assigned a Neurological Global Unique Identifier (NeuroGUID), and a predefined clinical dataset is captured in NeuroBANK™. All medications, including edaravone, are recorded. The dataset will be queried for edaravone use, duration of use, and selected clinical and demographic information. Results: As July of 2018, 105 of 419 consented PALS had received edaravone. Ten PALS were not included due to incomplete data. Of the remaining 95, 61 are male, 34 are female, and age range is from 37 to 82 years. Sixteen PALS (17%) have stopped edaravone, on average after 2.6 months of onset of treatment (range:treatment). Average ALSFRS-R score of all patients on edaravone was 33.6, and of the patients that discontinued the medication was 29.8. Enrollment has accelerated since that time and updated results, vital capacity slopes, and data for the aggregate population through March 2019 will be reported at the meeting. Conclusions: The ALS Natural History Study Consortium provides an opportunity to participating sites to aggregate heterogeneous patient population, and to provide usage and efficacy information on concomitant medications, including post-marketing review of approved drugs as edaravone